Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma. 2020

Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
Department of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX 79601.

Preclinical studies demonstrated that complement promotes tumor growth. Therefore, we sought to determine the best target for complement-based therapy among common human malignancies. High expression of 11 complement genes was linked to unfavorable prognosis in renal cell carcinoma. Complement protein expression or deposition was observed mainly in stroma, leukocytes, and tumor vasculature, corresponding to a role of complement in regulating the tumor microenvironment. Complement abundance in tumors correlated with a high nuclear grade. Complement genes clustered within an aggressive inflammatory subtype of renal cancer characterized by poor prognosis, markers of T cell dysfunction, and alternatively activated macrophages. Plasma levels of complement proteins correlated with response to immune checkpoint inhibitors. Corroborating human data, complement deficiencies and blockade reduced tumor growth by enhancing antitumor immunity and seemingly reducing angiogenesis in a mouse model of kidney cancer resistant to PD-1 blockade. Overall, this study implicates complement in the immune landscape of renal cell carcinoma, and notwithstanding cohort size and preclinical model limitations, the data suggest that tumors resistant to immune checkpoint inhibitors might be suitable targets for complement-based therapy.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System

Related Publications

Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
June 2025, Discover oncology,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
January 2025, Oncology research,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
July 2025, BMC oral health,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
May 2017, Urologic oncology,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
July 2021, Cells,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
January 2019, Journal of medical genetics,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
January 2022, American journal of cancer research,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
January 2022, Frontiers in oncology,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
January 2018, European review for medical and pharmacological sciences,
Britney Reese, and Ashok Silwal, and Elizabeth Daugherity, and Michael Daugherity, and Mahshid Arabi, and Pierce Daly, and Yvonne Paterson, and Layton Woolford, and Alana Christie, and Roy Elias, and James Brugarolas, and Tao Wang, and Magdalena Karbowniczek, and Maciej M Markiewski
March 2018, European review for medical and pharmacological sciences,
Copied contents to your clipboard!